Semaglutide
A synthetic GLP-1 analogue with a C18 fatty-diacid modification enabling once-weekly subcutaneous dosing; FDA-approved as Ozempic for type 2 diabetes (2017), Wegovy for chronic weight management (2021), and Rybelsus as an oral formulation for type 2 diabetes (2019). Phase 3 RCT data from the SUSTAIN and STEP programmes demonstrate consistent glycaemic control and 9–15% weight reduction versus placebo; the SELECT trial reported a 20% reduction in cardiovascular events. This is among the most extensively evidenced compounds reviewed on this platform.
Side effects & risks
Semaglutide's adverse-event profile is among the most extensively characterised of any compound reviewed on this platform, evaluated in multiple large Phase 3 trials across both T2D and obesity populations with post-marketing pharmacovigilance accumulating across global approval. The following applies to the approved pharmaceutical products (Ozempic, Wegovy, Rybelsus). Compounded and research-chemical preparations have not undergone equivalent characterisation.
Gastrointestinal adverse events: The most common adverse events are gastrointestinal — nausea, vomiting, diarrhoea, and constipation — and represent the primary tolerability burden of the GLP-1 receptor agonist class. In STEP 1 (Wilding et al., 2021, New England Journal of Medicine; PMID 33567185), nausea occurred in 44.2% of semaglutide participants versus 16.1% placebo; vomiting in 24.8% versus 6.8%; diarrhoea in 29.7% versus 16.1%. GI events were predominantly mild to moderate in severity, most frequent during the dose-escalation phase, and generally decreased over time. Approximately 4.5% of semaglutide participants discontinued due to GI adverse events versus 0.8% placebo. The gradual dose-escalation schedules for Ozempic and Wegovy are designed to reduce GI burden during initiation.
Thyroid C-cell tumour risk — FDA Boxed Warning: The prescribing information for all semaglutide formulations carries an FDA Boxed Warning regarding the risk of thyroid C-cell tumours. Rodent carcinogenicity studies demonstrated dose-dependent and duration-dependent thyroid C-cell adenomas and carcinomas with semaglutide and across the GLP-1 receptor agonist class. The human relevance of this rodent signal has not been established; human thyroid tissue expresses GLP-1R at substantially lower levels than rodent thyroid, and no excess medullary thyroid carcinoma signal has been detected in clinical trials or post-marketing surveillance to date. Because the risk cannot be excluded, semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2). Patients should be advised to report neck mass, dysphagia, dysphonia, or dyspnoea. This warning applies to all approved semaglutide formulations and to the GLP-1 receptor agonist class.
Pancreatitis: Acute pancreatitis — including fatal and non-fatal cases — has been reported in association with GLP-1 receptor agonists including semaglutide. The prescribing information recommends discontinuation if pancreatitis is suspected and non-reinitiation if confirmed. A direct causal relationship has not been definitively established, but the association is a recognised class-relevant risk. Patients with a prior history of pancreatitis should discuss this risk with a clinician before initiating semaglutide.
Gallbladder disease: Cholelithiasis and cholecystitis have been reported with semaglutide. In Wegovy clinical trials, cholelithiasis occurred in 2.3% of semaglutide-treated participants versus 0.8% placebo. Rapid weight loss is independently associated with gallstone formation and may contribute to this excess.
Hypoglycaemia: As monotherapy, semaglutide's glucose-dependent insulin secretion mechanism substantially limits hypoglycaemia risk; symptomatic hypoglycaemia rates as monotherapy were comparable to placebo in Phase 3 trials. When semaglutide is combined with insulin secretagogues (sulfonylureas, meglitinides) or insulin, hypoglycaemia risk is meaningfully increased. Dose reduction of concomitant insulin secretagogues or insulin is recommended when initiating semaglutide.
Heart rate increase: Semaglutide produces a small but consistent increase in mean resting heart rate — approximately 2-3 beats per minute above baseline across Phase 3 trials. Clinical significance is unclear for most patients; monitoring is appropriate in patients with cardiac conditions where heart rate elevation is a concern.
Injection-site reactions: Local reactions at subcutaneous injection sites (redness, swelling, pain, bruising) are reported at low frequency and are generally mild. Rotating injection sites is recommended.
Acute kidney injury: Acute kidney injury — occasionally requiring haemodialysis — has been reported, predominantly in the context of severe GI adverse events causing dehydration. Maintaining adequate hydration during GI illness is important.
Hypersensitivity: Anaphylaxis and angioedema have been reported with GLP-1 receptor agonists. Patients experiencing symptoms of a serious hypersensitivity reaction should seek immediate medical care and should not continue semaglutide.
Semaglutide is a prescription drug. The benefit-risk characterisation in Phase 3 trials applies to the approved pharmaceuticals. Compounded and research-chemical preparations have not been evaluated under equivalent conditions.
Evidence summary
Latest studies
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
Researchers interviewed eleven people with schizophrenia who had received semaglutide during a randomized trial on antipsychotic-related prediabetes. Participants described an intense, unrelenting hunger they attributed to their antipsychotic medication, and most experienced the drop in that hunger on semaglutide as a relief. Several also described downsides once appetite fell, including losing eating as a source of comfort and structure in the day.
ATR-FTIR spectroscopy coupled with multivariate analysis for monitoring degradation and secondary structure transitions in therapeutic peptide formulations.
This is an analytical chemistry paper testing whether infrared spectroscopy (ATR-FTIR) plus statistical pattern analysis can quickly detect when a peptide formulation has started to break down. Semaglutide and liraglutide were used as stand-in model compounds, stressed under various conditions, and read as dry films. The method picked up subtle shifts in protein folding in the amide I spectral region and could separate samples by stress condition, with results matching what mass spectrometry and chromatography showed. The authors frame it as a proof of concept for stability monitoring, process control, and product authentication.
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Chemists took the short segment of semaglutide that engages the GLP-1 receptor and rebuilt it as a stapled peptide - a chemical bridge that locks the molecule into its active shape - designing 108 candidates and synthesising 35 of them. Most of the stapled versions survived longer in serum and resisted enzymatic breakdown better than semaglutide itself, with three standing out. Computer simulations suggested the best candidates still fit the receptor, but no cell or animal activity data are reported.
Community discussion
Community-reported · not verified
These are synthesised observations from public forum discussions. They are community-reported, not clinically verified, and should not inform any health decision. The peptide does not cure, treat, or prevent any condition based on these reports.
“Palpitations on Reta, shall I re try with ozempic?”
A user reports palpitations while using retatrutide and asks whether switching to semaglutide (Ozempic) would be a reasonable next step. Palpitations and elevated heart rate are a recurring community-reported side effect for the triple agonist; no replies were pulled.
“Weight loss drugs may help with mental health. People with bipolar disorder who were taking semaglutide (otherwise known as Ozempic or Wegovy), a type of GLP-1 medication, had significantly lower rates of psychiatric hospitalization compared with periods when they were not taking GLP-1 medications,"”
r/science thread on a study reporting that people with bipolar disorder had significantly lower rates of psychiatric hospitalization during periods on semaglutide (Ozempic/Wegovy) compared with periods off GLP-1 medication, using a within-person comparison design.
“Study finds GLP1 semaglutide reduced systemic inflammation within weeks, before substantial weight loss, and lowered MACE (major adverse cardiovascular events) risk even without weight loss”
Discussion of a study reporting that semaglutide was associated with reduced systemic inflammation within weeks of initiation, before substantial weight loss occurred, and with lower major adverse cardiovascular event risk even in participants without meaningful weight change. Commenters read the results as evidence for weight-independent mechanisms of GLP-1 receptor agonists, a question of active interest in the cardiometabolic literature.
“Semaglutide linked to 26% lower 5-year predicted dementia risk”
Discussion of a study reporting that semaglutide use was associated with a 26% lower 5-year predicted dementia risk, adding to the growing research interest in GLP-1 receptor agonists' possible neurocognitive effects; the finding is observational and predictive rather than a demonstrated causal outcome.
“From Insulin to the GLP-1 Boom: A Short History of Peptide Therapy”
A historical overview tracing peptide therapeutics from the discovery of insulin through to the current GLP-1 receptor agonist era, contextualizing modern agents such as semaglutide and tirzepatide within a century of drug development.
Reported protocols (with caveats)
| USE | ROUTE | COMMON DOSE | FREQUENCY | TYPICAL CYCLE |
|---|---|---|---|---|
| Type 2 diabetes (Ozempic, FDA-approved) | SC injection (abdomen, upper arm, or thigh) | 0.25 mg -> 0.5 mg -> 1.0 mg -> 2.0 mg | Once weekly | Maintenance; escalate on 4-week minimum intervals per prescribing information |
| Chronic weight management (Wegovy, FDA-approved) | SC injection (abdomen, upper arm, or thigh) | 0.25 mg -> 0.5 mg -> 1.0 mg -> 1.7 mg -> 2.4 mg | Once weekly | 16-week escalation to 2.4 mg maintenance; concurrent lifestyle modification required |
| Type 2 diabetes (Rybelsus oral, FDA-approved) | Oral tablet (fasting, <=120 mL water, >=30 min before food) | 3 mg -> 7 mg -> 14 mg | Once daily | 30-day intervals per escalation step; not approved for weight management |
Frequently asked questions
- What is semaglutide approved for?
- Semaglutide is FDA-approved in three formulations: Ozempic (subcutaneous injection, December 2017) for type 2 diabetes management and cardiovascular risk reduction in adults with T2D and established cardiovascular disease; Wegovy (subcutaneous injection, June 2021) for chronic weight management in adults with BMI >=30 kg/m2 or >=27 kg/m2 with at least one weight-related comorbidity, with an expanded cardiovascular indication following the SELECT trial (Lincoff et al., 2023, PMID 37952131); and Rybelsus (oral tablet, September 2019) for type 2 diabetes management. All formulations require a prescription.
- What weight loss does Wegovy (semaglutide 2.4 mg) produce in clinical trials?
- Clinical trial results describe population averages and should not be interpreted as individual predictions. In STEP 1 (Wilding et al., 2021, New England Journal of Medicine; PMID 33567185), adults with overweight or obesity without type 2 diabetes treated with semaglutide 2.4 mg weekly for 68 weeks lost a mean of 14.9% of initial body weight versus 2.4% with placebo; 86% of semaglutide participants versus 32% of placebo participants achieved >=5% weight loss. In STEP 2 (Davies et al., 2021, Lancet; PMID 33667417), adults with type 2 diabetes and overweight/obesity lost a mean of 9.6% of body weight with semaglutide 2.4 mg versus 3.4% with placebo.
- What is the most serious safety warning for semaglutide?
- The FDA Boxed Warning on all semaglutide prescribing information concerns the risk of thyroid C-cell tumours. Rodent carcinogenicity studies demonstrated dose-dependent thyroid C-cell adenomas and carcinomas; the human relevance is not established but cannot be excluded. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2). Patients should report neck mass, dysphagia, dysphonia, or dyspnoea. This is a class-wide warning for GLP-1 receptor agonists.
- What is the difference between semaglutide and tirzepatide?
- Semaglutide is a selective GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates two incretin receptors simultaneously (GIP-R and GLP-1R). In SURPASS-2 (Frias et al., 2021, New England Journal of Medicine; PMID 34170647), tirzepatide at 5, 10, and 15 mg weekly produced greater HbA1c reductions and body weight loss than semaglutide 1 mg weekly in T2D patients — though the higher 2 mg semaglutide dose was not included. No published Phase 3 trial has directly compared tirzepatide to high-dose semaglutide 2.4 mg for weight management.
- Is compounded semaglutide the same as Ozempic or Wegovy?
- No. During FDA-designated drug shortage periods, compounding pharmacies were permitted to produce semaglutide preparations under Section 503A and 503B exemptions. These products have not been evaluated for safety or efficacy in the same clinical trial framework as the branded pharmaceuticals; they differ in formulation, excipients, and dose-verification standards. Following shortage resolution, the FDA announced enforcement actions against compounders. Research-chemical semaglutide from non-pharmacy suppliers lacks pharmaceutical manufacturing controls entirely.